Apolipoprotein C-III

<p>This section provides any useful information about the protein, mostly biological knowledge.<p><a href='/help/function_section' target='_top'>More...</a></p>Functionⁱ

Sites

<p>The <a href="http://www.geneontology.org/">Gene Ontology (GO)</a> project provides a set of hierarchical controlled vocabulary split into 3 categories:<p><a href='/help/gene_ontology' target='_top'>More...</a></p>GO - Molecular functionⁱ

• cholesterol binding Source: BHF-UCL <p>Inferred by Curator</p> <p>Used for cases where an annotation is not supported by any evidence but can be reasonably inferred by a curator from other GO annotations for which evidence <br />is available.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ic">GO evidence code guide</a></p> Inferred by curatorⁱ
  • "Apolipoprotein specificity for lipid efflux by the human ABCAI transporter."
    Remaley A.T., Stonik J.A., Demosky S.J., Neufeld E.B., Bocharov A.V., Vishnyakova T.G., Eggerman T.L., Patterson A.P., Duverger N.J., Santamarina-Fojo S., Brewer H.B. Jr.
    Biochem. Biophys. Res. Commun. 280:818-823(2001) [PubMed] [Europe PMC] [Abstract]
• enzyme regulator activity Source: BHF-UCL <p>Inferred from Direct Assay</p> <p>Used to indicate a direct assay for the function, process or component indicated by the GO term.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ida">GO evidence code guide</a></p> Inferred from direct assayⁱ
  • "Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr."
    Liu H., Labeur C., Xu C.F., Ferrell R., Lins L., Brasseur R., Rosseneu M., Weiss K.M., Humphries S.E., Talmud P.J.
    J. Lipid Res. 41:1760-1771(2000) [PubMed] [Europe PMC] [Abstract]
• high-density lipoprotein particle receptor binding Source: BHF-UCL <p>Inferred from Physical Interaction</p> <p>Covers physical interactions between the gene product of interest and another molecule (or ion, or complex).</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#ipi">GO evidence code guide</a></p> Inferred from physical interactionⁱ
  • "Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake."
    Xu S., Laccotripe M., Huang X., Rigotti A., Zannis V.I., Krieger M.
    J. Lipid Res. 38:1289-1298(1997) [PubMed] [Europe PMC] [Abstract]
• lipase inhibitor activity Source: BHF-UCLInferred from direct assayⁱ
  • "Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL."
    Berbee J.F., van der Hoogt C.C., Sundararaman D., Havekes L.M., Rensen P.C.
    J. Lipid Res. 46:297-306(2005) [PubMed] [Europe PMC] [Abstract]
  • "Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase."
    Kinnunen P.K., Ehnolm C.
    FEBS Lett. 65:354-357(1976) [PubMed] [Europe PMC] [Abstract]
  • "Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding."
    Dorfmeister B., Zeng W.W., Dichlberger A., Nilsson S.K., Schaap F.G., Hubacek J.A., Merkel M., Cooper J.A., Lookene A., Putt W., Whittall R., Lee P.J., Lins L., Delsaux N., Nierman M., Kuivenhoven J.A., Kastelein J.J., Vrablik M.

    , Olivecrona G., Schneider W.J., Heeren J., Humphries S.E., Talmud P.J.
    Arterioscler. Thromb. Vasc. Biol. 28:1866-1871(2008) [PubMed] [Europe PMC] [Abstract]
  • "Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III."
    Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P.
    J. Clin. Invest. 75:384-390(1985) [PubMed] [Europe PMC] [Abstract]
• phospholipid binding Source: BHF-UCLInferred from direct assayⁱ
  • "Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr."
    Liu H., Labeur C., Xu C.F., Ferrell R., Lins L., Brasseur R., Rosseneu M., Weiss K.M., Humphries S.E., Talmud P.J.
    J. Lipid Res. 41:1760-1771(2000) [PubMed] [Europe PMC] [Abstract]
  • "Behavior of human apolipoprotein E in aqueous solutions and at interfaces."
    Yokoyama S., Kawai Y., Tajima S., Yamamoto A.
    J. Biol. Chem. 260:16375-16382(1985) [PubMed] [Europe PMC] [Abstract]

GO - Biological processⁱ

• cholesterol efflux Source: BHF-UCLInferred from direct assayⁱ
  • "Apolipoprotein specificity for lipid efflux by the human ABCAI transporter."
    Remaley A.T., Stonik J.A., Demosky S.J., Neufeld E.B., Bocharov A.V., Vishnyakova T.G., Eggerman T.L., Patterson A.P., Duverger N.J., Santamarina-Fojo S., Brewer H.B. Jr.
    Biochem. Biophys. Res. Commun. 280:818-823(2001) [PubMed] [Europe PMC] [Abstract]
  • "Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter."
    Nofer J.R., Remaley A.T., Feuerborn R., Wolinnska I., Engel T., von Eckardstein A., Assmann G.
    J. Lipid Res. 47:794-803(2006) [PubMed] [Europe PMC] [Abstract]
• cholesterol homeostasis Source: BHF-UCL <p>Inferred from Mutant Phenotype</p> <p>Describes annotations that are concluded from looking at variations or changes in a gene product such as mutations or abnormal levels and includes techniques such as knockouts, overexpression, anti-sense experiments and use of specific protein inhibitors.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#imp">GO evidence code guide</a></p> Inferred from mutant phenotypeⁱ
  • "ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia."
    Kypreos K.E.
    Biochemistry 47:10491-10502(2008) [PubMed] [Europe PMC] [Abstract]
• chylomicron assembly Source: Reactome
• chylomicron remnant clearance Source: BHF-UCLInferred from direct assayⁱ
  • "Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver."
    Windler E., Havel R.J.
    J. Lipid Res. 26:556-565(1985) [PubMed] [Europe PMC] [Abstract]
• chylomicron remodeling Source: Reactome
• G protein-coupled receptor signaling pathway Source: BHF-UCLInferred from direct assayⁱ
  • "Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter."
    Nofer J.R., Remaley A.T., Feuerborn R., Wolinnska I., Engel T., von Eckardstein A., Assmann G.
    J. Lipid Res. 47:794-803(2006) [PubMed] [Europe PMC] [Abstract]
• high-density lipoprotein particle remodeling Source: BHF-UCLInferred from mutant phenotypeⁱ
  • "Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice."
    Qu S., Perdomo G., Su D., D'Souza F.M., Shachter N.S., Dong H.H.
    J. Lipid Res. 48:1476-1487(2007) [PubMed] [Europe PMC] [Abstract]
• lipoprotein metabolic process Source: InterPro
• negative regulation of cholesterol import Source: BHF-UCLInferred from mutant phenotypeⁱ
  • "Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells."
    Huard K., Bourgeois P., Rhainds D., Falstrault L., Cohn J.S., Brissette L.
    Int. J. Biochem. Cell Biol. 37:1308-1318(2005) [PubMed] [Europe PMC] [Abstract]
• negative regulation of fatty acid biosynthetic process Source: BHF-UCLInferred from direct assayⁱ
  • "Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr."
    Liu H., Labeur C., Xu C.F., Ferrell R., Lins L., Brasseur R., Rosseneu M., Weiss K.M., Humphries S.E., Talmud P.J.
    J. Lipid Res. 41:1760-1771(2000) [PubMed] [Europe PMC] [Abstract]
  • "Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding."
    Dorfmeister B., Zeng W.W., Dichlberger A., Nilsson S.K., Schaap F.G., Hubacek J.A., Merkel M., Cooper J.A., Lookene A., Putt W., Whittall R., Lee P.J., Lins L., Delsaux N., Nierman M., Kuivenhoven J.A., Kastelein J.J., Vrablik M.

    , Olivecrona G., Schneider W.J., Heeren J., Humphries S.E., Talmud P.J.
    Arterioscler. Thromb. Vasc. Biol. 28:1866-1871(2008) [PubMed] [Europe PMC] [Abstract]
• negative regulation of high-density lipoprotein particle clearance Source: BHF-UCLInferred from mutant phenotypeⁱ
  • "Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells."
    Huard K., Bourgeois P., Rhainds D., Falstrault L., Cohn J.S., Brissette L.
    Int. J. Biochem. Cell Biol. 37:1308-1318(2005) [PubMed] [Europe PMC] [Abstract]
• negative regulation of lipid catabolic process Source: BHF-UCLInferred from direct assayⁱ
  • "Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL."
    Berbee J.F., van der Hoogt C.C., Sundararaman D., Havekes L.M., Rensen P.C.
    J. Lipid Res. 46:297-306(2005) [PubMed] [Europe PMC] [Abstract]
• negative regulation of lipid metabolic process Source: BHF-UCLInferred from direct assayⁱ
  • "Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase."
    Kinnunen P.K., Ehnolm C.
    FEBS Lett. 65:354-357(1976) [PubMed] [Europe PMC] [Abstract]
• negative regulation of lipoprotein lipase activity Source: BHF-UCLInferred from direct assayⁱ
  • "Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr."
    Liu H., Labeur C., Xu C.F., Ferrell R., Lins L., Brasseur R., Rosseneu M., Weiss K.M., Humphries S.E., Talmud P.J.
    J. Lipid Res. 41:1760-1771(2000) [PubMed] [Europe PMC] [Abstract]
  • "Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding."
    Dorfmeister B., Zeng W.W., Dichlberger A., Nilsson S.K., Schaap F.G., Hubacek J.A., Merkel M., Cooper J.A., Lookene A., Putt W., Whittall R., Lee P.J., Lins L., Delsaux N., Nierman M., Kuivenhoven J.A., Kastelein J.J., Vrablik M.

    , Olivecrona G., Schneider W.J., Heeren J., Humphries S.E., Talmud P.J.
    Arterioscler. Thromb. Vasc. Biol. 28:1866-1871(2008) [PubMed] [Europe PMC] [Abstract]
  • "Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III."
    Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P.
    J. Clin. Invest. 75:384-390(1985) [PubMed] [Europe PMC] [Abstract]
• negative regulation of low-density lipoprotein particle clearance Source: BHF-UCLInferred from mutant phenotypeⁱ
  • "Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells."
    Huard K., Bourgeois P., Rhainds D., Falstrault L., Cohn J.S., Brissette L.
    Int. J. Biochem. Cell Biol. 37:1308-1318(2005) [PubMed] [Europe PMC] [Abstract]
• negative regulation of receptor-mediated endocytosis Source: BHF-UCLInferred from direct assayⁱ
  • "Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway."
    Sehayek E., Eisenberg S.
    J. Biol. Chem. 266:18259-18267(1991) [PubMed] [Europe PMC] [Abstract]
• negative regulation of triglyceride catabolic process Source: BHF-UCLInferred from direct assayⁱ
  • "Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding."
    Dorfmeister B., Zeng W.W., Dichlberger A., Nilsson S.K., Schaap F.G., Hubacek J.A., Merkel M., Cooper J.A., Lookene A., Putt W., Whittall R., Lee P.J., Lins L., Delsaux N., Nierman M., Kuivenhoven J.A., Kastelein J.J., Vrablik M.

    , Olivecrona G., Schneider W.J., Heeren J., Humphries S.E., Talmud P.J.
    Arterioscler. Thromb. Vasc. Biol. 28:1866-1871(2008) [PubMed] [Europe PMC] [Abstract]
  • "Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III."
    Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P.
    J. Clin. Invest. 75:384-390(1985) [PubMed] [Europe PMC] [Abstract]
• negative regulation of very-low-density lipoprotein particle clearance Source: BHF-UCLInferred from direct assayⁱ
  • "Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway."
    Sehayek E., Eisenberg S.
    J. Biol. Chem. 266:18259-18267(1991) [PubMed] [Europe PMC] [Abstract]
• negative regulation of very-low-density lipoprotein particle remodeling Source: BHF-UCLInferred from direct assayⁱ
  • "Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III."
    Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P.
    J. Clin. Invest. 75:384-390(1985) [PubMed] [Europe PMC] [Abstract]
• phospholipid efflux Source: BHF-UCLInferred from direct assayⁱ
  • "Apolipoprotein specificity for lipid efflux by the human ABCAI transporter."
    Remaley A.T., Stonik J.A., Demosky S.J., Neufeld E.B., Bocharov A.V., Vishnyakova T.G., Eggerman T.L., Patterson A.P., Duverger N.J., Santamarina-Fojo S., Brewer H.B. Jr.
    Biochem. Biophys. Res. Commun. 280:818-823(2001) [PubMed] [Europe PMC] [Abstract]
• regulation of Cdc42 protein signal transduction Source: BHF-UCLInferred from direct assayⁱ
  • "Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter."
    Nofer J.R., Remaley A.T., Feuerborn R., Wolinnska I., Engel T., von Eckardstein A., Assmann G.
    J. Lipid Res. 47:794-803(2006) [PubMed] [Europe PMC] [Abstract]
• retinoid metabolic process Source: Reactome
• reverse cholesterol transport Source: BHF-UCLInferred by curatorⁱ
  • "Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice."
    Qu S., Perdomo G., Su D., D'Souza F.M., Shachter N.S., Dong H.H.
    J. Lipid Res. 48:1476-1487(2007) [PubMed] [Europe PMC] [Abstract]
• triglyceride catabolic process Source: BHF-UCLInferred from direct assayⁱ
  • "Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr."
    Liu H., Labeur C., Xu C.F., Ferrell R., Lins L., Brasseur R., Rosseneu M., Weiss K.M., Humphries S.E., Talmud P.J.
    J. Lipid Res. 41:1760-1771(2000) [PubMed] [Europe PMC] [Abstract]
• triglyceride homeostasis Source: BHF-UCLInferred from mutant phenotypeⁱ
  • "ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia."
    Kypreos K.E.
    Biochemistry 47:10491-10502(2008) [PubMed] [Europe PMC] [Abstract]
• triglyceride metabolic process Source: HGNCInferred from mutant phenotypeⁱ
  • "Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study."
    Hallman D.M., Srinivasan S.R., Chen W., Boerwinkle E., Berenson G.S.
    Metab. Clin. Exp. 55:1574-1581(2006) [PubMed] [Europe PMC] [Abstract]
• very-low-density lipoprotein particle assembly Source: BHF-UCL <p>Traceable Author Statement</p> <p>Used for information from review articles where the original experiments are traceable through that article and also for information from text books or dictionaries.</p> <p>More information in the <a href="http://geneontology.org/page/guide-go-evidence-codes#tas">GO evidence code guide</a></p> Traceable author statementⁱ
  • "Apolipoprotein C-III: understanding an emerging cardiovascular risk factor."
    Ooi E.M., Barrett P.H., Chan D.C., Watts G.F.
    Clin. Sci. 114:611-624(2008) [PubMed] [Europe PMC] [Abstract]

<p>UniProtKB Keywords constitute a <a href="http://www.uniprot.org/keywords">controlled vocabulary</a> with a hierarchical structure. Keywords summarise the content of a UniProtKB entry and facilitate the search for proteins of interest.<p><a href='/help/keywords' target='_top'>More...</a></p>Keywordsⁱ

Enzyme and pathway databases

<p>This section provides information about the protein and gene name(s) and synonym(s) and about the organism that is the source of the protein sequence.<p><a href='/help/names_and_taxonomy_section' target='_top'>More...</a></p>Names & Taxonomyⁱ

Organism-specific databases

<p>This section provides information on the location and the topology of the mature protein in the cell.<p><a href='/help/subcellular_location_section' target='_top'>More...</a></p>Subcellular locationⁱ

Keywords - Cellular componentⁱ

<p>This section provides information on the disease(s) and phenotype(s) associated with a protein.<p><a href='/help/pathology_and_biotech_section' target='_top'>More...</a></p>Pathology & Biotechⁱ

<p>This subsection of the ‘Pathology and Biotech’ section provides information on the disease(s) associated with genetic variations in a given protein. The information is extracted from the scientific literature and diseases that are also described in the <a href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim">OMIM</a> database are represented with a <a href="http://www.uniprot.org/diseases">controlled vocabulary</a> in the following way:<p><a href='/help/involvement_in_disease' target='_top'>More...</a></p>Involvement in diseaseⁱ

Keywords - Diseaseⁱ

Organism-specific databases

Miscellaneous databases

Chemistry databases

Polymorphism and mutation databases

<p>This section describes post-translational modifications (PTMs) and/or processing events.<p><a href='/help/ptm_processing_section' target='_top'>More...</a></p>PTM / Processingⁱ

Molecule processing

Amino acid modifications

<p>This subsection of the <a href="http://www.uniprot.org/help/ptm_processing_section">PTM/processing</a> section describes post-translational modifications (PTMs). This subsection <strong>complements</strong> the information provided at the sequence level or describes modifications for which <strong>position-specific data is not yet available</strong>.<p><a href='/help/post-translational_modification' target='_top'>More...</a></p>Post-translational modificationⁱ

Keywords - PTMⁱ

Proteomic databases

2D gel databases

PTM databases

<p>This section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms.<p><a href='/help/expression_section' target='_top'>More...</a></p>Expressionⁱ

<p>This subsection of the ‘Expression’ section provides information on the expression of a gene at the mRNA or protein level in cells or in tissues of multicellular organisms. By default, the information is derived from experiments at the mRNA level, unless specified ‘at protein level’. <br></br>Examples: <a href="http://www.uniprot.org/uniprot/P92958#expression">P92958</a>, <a href="http://www.uniprot.org/uniprot/Q8TDN4#expression">Q8TDN4</a>, <a href="http://www.uniprot.org/uniprot/O14734#expression">O14734</a><p><a href='/help/tissue_specificity' target='_top'>More...</a></p>Tissue specificityⁱ

Gene expression databases

Organism-specific databases

<p>This section provides information on the quaternary structure of a protein and on interaction(s) with other proteins or protein complexes.<p><a href='/help/interaction_section' target='_top'>More...</a></p>Interactionⁱ

GO - Molecular functionⁱ

• high-density lipoprotein particle receptor binding Source: BHF-UCLInferred from physical interactionⁱ
  • "Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake."
    Xu S., Laccotripe M., Huang X., Rigotti A., Zannis V.I., Krieger M.
    J. Lipid Res. 38:1289-1298(1997) [PubMed] [Europe PMC] [Abstract]

Protein-protein interaction databases

<p>This section provides information on the tertiary and secondary structure of a protein.<p><a href='/help/structure_section' target='_top'>More...</a></p>Structureⁱ

Secondary structure

3D structure databases

Miscellaneous databases

<p>This section provides information on sequence similarities with other proteins and the domain(s) present in a protein.<p><a href='/help/family_and_domains_section' target='_top'>More...</a></p>Family & Domainsⁱ

Region

<p>This subsection of the ‘Family and domains’ section provides information about the sequence similarity with other proteins.<p><a href='/help/sequence_similarities' target='_top'>More...</a></p>Sequence similaritiesⁱ

Keywords - Domainⁱ

Phylogenomic databases

Family and domain databases

<p>This section displays by default the canonical protein sequence and upon request all isoforms described in the entry. It also includes information pertinent to the sequence(s), including <a href="http://www.uniprot.org/help/sequence_length">length</a> and <a href="http://www.uniprot.org/help/sequences">molecular weight</a>. The information is filed in different subsections. The current subsections and their content are listed below:<p><a href='/help/sequences_section' target='_top'>More...</a></p>Sequence (1+)ⁱ

<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is complete or not.<p><a href='/help/sequence_status' target='_top'>More...</a></p>Sequence statusⁱ: Complete.

<p>This subsection of the <a href="http://www.uniprot.org/help/sequences_section">Sequence</a> section indicates if the <a href="http://www.uniprot.org/help/canonical_and_isoforms">canonical sequence</a> displayed by default in the entry is in its mature form or if it represents the precursor.<p><a href='/help/sequence_processing' target='_top'>More...</a></p>Sequence processingⁱ: The displayed sequence is further processed into a mature form.

This entry has 1 described isoform and 2 potential isoforms that are computationally mapped.Show allAlign All

        10         20         30         40         50
MQPRVLLVVA LLALLASARA SEAEDASLLS FMQGYMKHAT KTAKDALSSV 
        60         70         80         90 
QESQVAQQAR GWVTDGFSSL KDYWSTVKDK FSEFWDLDPE VRPTSAVAA  

Experimental Info

Natural variant

Sequence databases

Genome annotation databases

Keywords - Coding sequence diversityⁱ

<p>This section provides links to proteins that are similar to the protein sequence(s) described in this entry at different levels of sequence identity thresholds (100%, 90% and 50%) based on their membership in UniProt Reference Clusters (<a href="http://www.uniprot.org/help/uniref">UniRef</a>).<p><a href='/help/similar_proteins_section' target='_top'>More...</a></p>Similar proteinsⁱ

• 100% Identity
• 90% Identity
• 50% Identity

<p>This section is used to point to information related to entries and found in data collections other than UniProtKB.<p><a href='/help/cross_references_section' target='_top'>More...</a></p>Cross-referencesⁱ

Sequence databases

3D structure databases

Protein-protein interaction databases

Chemistry databases

PTM databases

Polymorphism and mutation databases

2D gel databases

Proteomic databases

Protocols and materials databases

Genome annotation databases

Organism-specific databases

Phylogenomic databases

Enzyme and pathway databases

Miscellaneous databases

Gene expression databases

Family and domain databases

<p>This section provides general information on the entry.<p><a href='/help/entry_information_section' target='_top'>More...</a></p>Entry informationⁱ

<p>This section contains any relevant information that doesn’t fit in any other defined sections<p><a href='/help/miscellaneous_section' target='_top'>More...</a></p>Miscellaneousⁱ

Keywords - Technical termⁱ

Documents

1. PDB cross-references
   Index of Protein Data Bank (PDB) cross-references
2. SIMILARITY comments
   Index of protein domains and families
3. Human polymorphisms and disease mutations
   Index of human polymorphisms and disease mutations
4. MIM cross-references
   Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot
5. Human chromosome 11
   Human chromosome 11: entries, gene names and cross-references to MIM
6. Human entries with polymorphisms or disease mutations
   List of human entries with polymorphisms or disease mutations